April 25th 2025
Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.
Researchers Develop Improved Flow Cytometric Score for MDS Diagnosis
Analysis Reveals High Cost of Discontinued HMA Treatment for MDS
Heterogenous Nature of MDS Warrants Further Research, Review Finds
For Patients With HMA-Resistant MDS, What Are Their Options?
Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS